Professor of Pediatrics, University of Minnesota
私信我主号→
Joined December 2009
- Tweets23
- Following5
- Followers2
- Likes3
Pinned Tweet
新人刚入推特 妹妹联系方式添加主号@XimonRamirez❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
❤️
Check out christopher moertel's fundraising page - join.ctf.org/fundraiser/7505…
At the Brain Cancer Symposium in Canada, sharing data from OX2 Therapeutics. Thank you @DIPGCollab
I'm excited to be part of this upcoming live discussion on MEK Inhibitors in Neurofibromatosis Type 1 presented by @cec_onc! Tune in online on 5/8 at 12:15p ET & earn 1.0 free #CME/CE credit ➡️ ce.ceconcepts.com/MMS-153 #MedX #MedEd
More on the ReNeu trial of mirdametinib for Neurofibromatosis, type 1 linkedin.com/posts/oncodaily…
I hope that these data will help to bring mirdametinib to people living with neurofibromatosis, type 1. Thank you to SpringWorks Therapeutics, my co-authors, and the patients and families who contributed their time and effort to making this clinical trial successful.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
I am honored to be lead author on this publication.
